key: cord-0942949-dmlqkl4s
authors: Kirschner, Janbernd; Butoianu, Nina; Goemans, Nathalie; Haberlova, Jana; Kostera-Pruszczyk, Anna; Mercuri, Eugenio; van der Pol, W. Ludo; Quijano-Roy, Susana; Sejersen, Thomas; Tizzano, Eduardo F.; Ziegler, Andreas; Servais, Laurent; Muntoni, Francesco
title: European ad-hoc consensus statement on gene replacement therapy for spinal muscular atrophy
date: 2020-07-09
journal: Eur J Paediatr Neurol
DOI: 10.1016/j.ejpn.2020.07.001
sha: 297cb91f04c796165bd0219b99d9904088a5c739
doc_id: 942949
cord_uid: dmlqkl4s

Spinal muscular atrophy (SMA) used to be one of the most common genetic causes of infant mortality. New disease modifying treatments have changed the disease trajectories and most impressive results are seen if treatment is initiated in the presymptomatic phase of the disease. Very recently, the European Medicine Agency approved Onasemnogene abeparvovec (Zolgensma®) for the treatment of patients with SMA with up to three copies of the SMN2 gene or the clinical presentation of SMA type 1. While this broad indication provides new opportunities, it also triggers discussions on the appropriate selection of patients in the context of limited available evidence. To aid the rational use of Onasemnogene abeparvovec for the treatment of SMA, a group of European neuromuscular experts presents in this paper eleven consensus statements covering qualification, patient selection, safety considerations and long-term monitoring.

Spinal muscular atrophy (SMA) is caused by autosomal recessive mutations of the SMN1 gene and is characterized by loss of motoneurons and progressive muscle weakness. The birth incidence of SMA is around 1 in 10,000 and it is thus classified as an orphan disease.

Disease severity covers a broad spectrum and onset ranges from neonatal period to adulthood, while onset in the first years of live is most common. (1) A highly homologous gene, SMN2, does not lead to disease but acts as a disease modifier. Higher SMN2 copy numbers are associated with milder phenotypes. (2) During the last decade, drug development for SMA has made dramatic progress and changed the disease outcome for many patients.

Nusinersen (Spinraza ® ) was the first drug that received approval for treatment of SMA by the European Medicine Agency (EMA). Nusinersen is an antisense-oligonucleotide that is administered intrathecally and increases SMN protein concentration by modifying the splicing of the SMN2 gene. Another splicing modifier is Risdiplam, a small molecule that is administered orally and is still in clinical development. (3) An alternative treatment strategy for SMA is gene replacement therapy. Onasemnogene abeparvovec (formerly AVXS-101, Zolgensma ® ) is an adeno-associated viral vector-based gene therapy designed to deliver a functional copy of the SMN1 gene to the motor neurons through a single intravenous infusion. (4) With a price around 2 million USD for a single dose, Zolgensma® has also attracted a great deal of attention as the most expensive drug on the market. In 2019 FDA approved the intravenous administration for the treatment of patients with SMA in the first two years of life independent of their disease severity. Recently, the EMA also approved Zolgensma ® for the treatment of SMA in Europe. The label covers two overlapping groups of patients, but does not define any age or weight limit: (5) • Patients with 5q spinal muscular atrophy (SMA) with a bi-allelic mutation in the SMN1 gene and a clinical diagnosis of SMA Type 1 • Patients with 5q SMA with a bi-allelic mutation in the SMN1 gene and up to 3 copies of the SMN2 gene.

According to this broad label a large number of patients with SMA would theoretically be eligible for treatment with Zolgensma ® . However, available data from clinical trials cover only patients during the first six months of life with a weight below 8.4 kg and little is known about the safety and efficacy of Zolgensma ® in older or heavier patients. This discrepancy poses major challenges to patients, clinicians and payers associated with the question who should be treated under which circumstances, also in view of the fact that an effective and safe treatment, nusinersen, is already widely available in this patient population. While we acknowledge the need of a sound risk-benefit assessment for each individual patient and the diversity of societies and health systems across Europe, we also strongly believe that some general principles should be considered in these reflections. This ad-hoc consensus-based opinion statement aims to facilitate this process.

This consensus statement has been developed by a group of neuromuscular experts from a variety of countries across Europe. The size and composition of the group was determined to allow a broad representation but also to facilitate a consensus within an acceptable time frame. This was of particular importance as discussions about the indication and reimbursement of Zolgensma ® have already started in individual countries.

Given the time frame and the fact that all participating experts are very familiar with the limited published data on the use of Zolgensma ® for the treatment of SMA, and of the data on other approved therapeutic options, we decided that a systematic literature review was not necessary in advance of the consensus process.

Due to travel restrictions associated with the COVID-19 pandemic, an in-person meeting was not possible. To initiate the process, all co-authors participated in a two-hour video conference to agree on the consensus process and to identify potential areas where a consensus statement might be helpful. The areas of interest were then further specified in a shared online document and interactive discussion during a period of two weeks. After general consensus on the appropriate statements, we performed an anonymous voting with all experts on each statement using REDCap electronic data capture tools. With this final vote we aimed to avoid dominating influence of some experts and allow free expression of opinions. A consensus greater than 95% was considered "strong consensus", between 75 and 95% "consensus", and between 50 and 75% "majority consensus". If less than 50% approved a statement, it was labelled as "no consensus".

Selection criteria for gene therapy Consensus statement 1: Traditional SMA types (e.g. type 0, 1, 2, 3, 4) alone are not sufficient to define patient populations who might benefit most from gene therapy. In symptomatic patients age at onset, disease duration and motor function status at the start of treatment are the most important factors that predict response to treatment. Consensus statement 2: In presymptomatic patients SMN2 copy number is the most important predictor of clinical severity and age of onset. As long as no better biomarkers or predictors are available, treatment decisions for presymptomatic patients should primarily be based on SMN2 copy number. Determination of SMN2 copy number needs to be performed in an expert laboratory with adequate measures of quality control.

• Strength of consensus: Strong consensus (100%)

The growing evidence that initiation of disease-modifying treatments in the presymptomatic stages of SMA is associated with significantly better outcome (7) leads to an increasing number of newborn screening programs and patients who are diagnosed before they develop any symptoms. Consensus statement 3: Approval of gene therapy for SMA with Zolgensma ® is based on clinical trials with patients with SMA less than 6 months of age. Additional data of patients up to 2 years and weighing up to 13.5 kg are made public through congress presentations.

These data mainly come from non-systematic data collection in the US, where Zolgensma® is approved up to the age of 2 years. When administered after the age of 6 months and/or in advanced stages of the disease, parents or patients should clearly be made aware that there are so far no published data on efficacy and safety. In this patient population it is particularly important for physicians to discuss the benefit/risk ratio and to carefully manage parents' or patients' expectations.

• Strength of consensus: Strong consensus (100%)

The broad label for Zolgensma® clearly exceeds the age and weight limits that have been studied in clinical trials and does not imply that its use is effective and safe in all patients who meet the criteria. All clinical trials excluded patients in advanced stages of the disease.

The European Medicine Agency deployed a conditional marketing authorisation, which can be used if a medicine addresses an unmet medical need and the benefit of immediate availability outweighs the risk from less comprehensive data than normally required. Growing evidence suggests that early initiation of treatment in a less advanced disease stage is associated with better outcome. (11, 12) As the applied dose is proportional to the patient's body weight, treatment of heavier patients also implies a significantly higher total dose than previously used in clinical trials. It is possible that advanced disease stage and higher total dose have a negative impact on the risk-benefit ratio. Treating physicians, patients and families should be aware of these uncertainties, and also discuss other approved therapies in which the risk-benefit might be better known.

Consensus statement 4: In patients presenting symptoms at birth, treated after a long disease duration, or with already severe evolution, parents should be clearly made aware that despite the use of gene therapy there is a high risk of living with a very severe disability. Palliative care should be discussed as an alternative treatment option in these circumstances. As most patients will remain with significant disease burden even after application of gene therapy, treatment centres should also be capable to provide appropriate multidisciplinary care according to international consensus recommendations. (1, 26) National health systems need to ensure that treatment centres are appropriately qualified and provided with sufficient resources to implement, monitor and evaluate the use of gene therapy for SMA in the best possible manner.

Consensus statement 8: There is convincing evidence that early initiation of treatmentideally in the presymptomatic stage of the disease -is associated with markedly better outcome as compared to later start of treatment. Spinal Muscular Atrophy is therefore a good candidate for inclusion in newborn screening programs. In newly diagnosed patients any delay of treatment should be avoided. Ideally, the time frame between diagnosis and initiation of a disease modifying treatment should be no longer than 14 days. This is particularly important in infants due to the progressive course of the disease. 

Currently the number of subjects exposed to gene therapy with Zolgensma® is still limited.

Ongoing clinical trials and real-word experience will generate additional evidence including long-term effects. However, the fact that the data on safety and effectiveness are collected by different institutions such as pharmaceutical company, regulatory authorities and academic networks might impede to generate an integrated body of evidence in a timely manner. All contributing parties should make these data available in an unbiased manner. Identification of new safety signals is specifically important for orphan drugs where the experience is still limited at the time of approval. (35) Therefore, any new safety signal should not only be communicated with clinical trial sites but with all treatment centres.

Diagnosis and management of spinal muscular atrophy: Part 1: Recommendations for diagnosis, rehabilitation, orthopedic and nutritional care

Correlation between SMA type and SMN2 copy number revisited: An analysis of 625 unrelated Spanish patients and a compilation of 2834 reported cases

Advances in Treatment of Spinal Muscular Atrophy -New Phenotypes, New Challenges, New Implications for Care

Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy

Zolgensma marketing authorisation

Nusinersen treatment of spinal muscular atrophy: current knowledge and existing gaps

Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study

244th ENMC international workshop: Newborn screening in spinal muscular atrophy

Novel challenges in spinal muscular atrophy -How to screen and whom to treat?

Discrepancy in redetermination of SMN2 copy numbers in children with SMA

Clinical Evidence Supporting Early Treatment Of Patients With Spinal Muscular Atrophy: Current Perspectives

Impact of Age and Motor Function in a Phase 1/2A Study of Infants With SMA Type 1 Receiving Single-Dose Gene Replacement Therapy

Sitting in patients with spinal muscular atrophy type 1 treated with nusinersen

Under Treatment with Nusinersen within the Expanded Access Program in Germany

Nusinersen for SMA: expanded access programme

Expanded access program with Nusinersen in SMA type I in Italy: Strengths and pitfalls of a successful experience

Improving single injection CSF delivery of AAV9-mediated gene therapy for SMA: a dose-response study in mice and nonhuman primates

Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy

Effects of nusinersen after one year of treatment in 123 children with SMA type 1 or 2: a French real-life observational study

Nusinersen in adults with 5q spinal muscular atrophy: a non-interventional, multicentre, observational cohort study

Safety and Treatment Effects of Nusinersen in Longstanding Adult 5q-SMA Type 3 -A Prospective Observational Study

Nusinersen in type 1 spinal muscular atrophy: Twelve-month real-world data

Nusinersen for older patients with spinal muscular atrophy: A real-world clinical setting experience

Combination therapy with nusinersen and AVXS-101 in SMA type 1

Clinical outcome measures in spinal muscular atrophy

Diagnosis and management of spinal muscular atrophy: Part 2: Pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics

Newborn screening for 5q-linked spinal muscular atrophy IQWiG Reports -Commission No. S18-02

One Year of Newborn Screening for SMA -Results of a German Pilot Project

Nusinersen in patients older than 7 months with spinal muscular atrophy type 1: A cohort study

Nusinersen in type 1 SMA infants, children and young adults: Preliminary results on motor function

Stroke treatment: time is brain

Development of an academic disease registry for spinal muscular atrophy

SMArtCARE -A platform to collect real-life outcome data of patients with spinal muscular atrophy

Position Statement: Sharing of Clinical Research Data in Spinal Muscular Atrophy to Accelerate Research and Improve Outcomes for Patients

Evaluation of quantitative signal detection in EudraVigilance for orphan drugs: possible risk of false negatives

European ad-hoc consensus statement on gene replacement therapy for

Janbernd Kirschner received honoraria for participation in advisory boards and educational activities from Avexis

Nathalie Goemans: participated in ad hoc advisory board activities for Biogen, Avexis, Roche and has received speaker's fee for participation in symposia from Roche and Biogen

Jana Haberlova participated in advisory board activities and has received speaker's fee for participation in symposia for Biogen

Anna Kostera-Pruszczyk reports advisory board for Biogen

Tizzano reports grant support to conduct clinical trials on SMA from

Serves as a consultant to AveXis, Biogen, Biologix, Cytokinetics, Roche for participation to scientific advisory boards and participation in educational symposia

Cytokinetics and Scholar Rock; receiving honoraria from AveXis, Biogen, Roche, for participation to scientific advisory boards and participation in educational symposia; receiving investigator grant from Biogen for the iSMAc disease registry

Scholar Rock and Avexis zolgesma trials

and received honoraria for lectures and advisory board activities for Biogen

Thomas Sejersen: participated in and received honoraria for lectures and advisory board activities for Biogen

Ludo van der Pol participated in ad hoc advisory board activities for Biogen and Avexis and served as a member of the Data Monitoring Committee for Branaplam (Novartis)

Principal investigator for Jewelfish (Roche) and Topaz studies (Scholar Rock) and member of the scientific advisory board for SMA Europe

Andreas Ziegler reports personal fees and scientific funding from Biogen, personal fees from Avexis, outside the submitted work

Laurent Servais reports research support from Avexis, Roche and Biogen, and consultancy fees/board member of Avexis

Francesco Muntoni reports serving on the Pfizer Rare Diseases advisory board; acting as a consultant for AveXis, Biogen, Roche, Novartis; receiving honoraria from AveXis, Biogen, Roche, for participation to scientific advisory boards and participation in educational symposia; receiving investigator grant from Biogen for SMA REACH UK registry; acting as Principal investigator for Ionis / Biogen nusinersen trials ; Roche olesoxime and risdiplam trial and Avexis zolgesma trials

We would like to thank Adrian Tassoni and Johanna Andrae from the Clinical Trials Unit of the Medical Center -University of Freiburg, Germany, for setting up the anonymous online voting.

Kirschner J et al.

• Onasemnogene abeparvovec (Zolgensma ® ) is the first approved gene therapy for a neuromuscular disease• Treatment with Onasemnogene abeparvovec requires a thorough risk-benefit analysis for each individual patient• Gene therapy with Onasemnogene abeparvovec should only be used by qualified neuromuscular expert centres• Systematic real-world data collection and additional clinical trials are needed to fill evidence gaps concerning safety and efficacy